Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate

• Odyssey Health is a medical company developing unique, life-saving products that address unmet clinical needs such as concussion, which does not have an FDA-approved therapeutic
• The company has developed PRV-002, a neurosteroid for the treatment of concussion, and an intranasal delivery device that delivers the drug into the upper chamber of the nasal cavity for onward travel into the brain
• Odyssey’s just concluded Phase I clinical trial shows that PRV-002 is safe and well tolerated
• The findings from the study are likely to benefit the military as well as the NFL, given military personnel and players frequently suffer concussions

In 2002, NFL Pro Hall of Famer and former center Michael Lewis Webster became the first ex-NFL player to be diagnosed through autopsy with chronic traumatic encephalopathy (“CTE”), a degenerative brain disorder believed to be caused by repeated concussions (https://ibn.fm/ZxgeE). Since then, doctors, the NFL in general, and medical companies like Odyssey Health (OTC: ODYY) have learned a lot about concussions and CTE. On its part, the NFL has progressively implemented a raft of player safety policies aimed at protecting players.

Despite the spate of safety policies, which include fines and suspensions to players, football remains a dangerous sport that sees players with massive physiques collide with one another. It is no question that this physicality can cause damage to the brain and body, and a recent incident, which has elicited…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.